NAMS
Price
$18.90
Change
+$0.01 (+0.05%)
Updated
Nov 6 closing price
Capitalization
2.26B
116 days until earnings call
Intraday BUY SELL Signals
VERA
Price
$29.79
Change
-$0.36 (-1.19%)
Updated
Nov 6 closing price
Capitalization
2.15B
138 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NAMS vs VERA

NAMS vs VERA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
NAMS vs. VERA commentary
Nov 07, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NAMS is a Hold and VERA is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for NAMS with price predictions
Nov 06, 2026

NAMS in +7.00% Uptrend, growing for three consecutive days on November 04, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NAMS advanced for three days, in 202 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NAMS's RSI Oscillator exited the oversold zone, 17 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

NAMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NAMS as a result. In 61 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.

The Moving Average Convergence Divergence Histogram (MACD) for NAMS turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In 36 of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at 63%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NAMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

The Aroon Indicator for NAMS entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.578) is normal, around the industry mean (3.482). P/E Ratio (-8.750) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (357.143) is also within normal values, averaging (440.869).

The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NAMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. NAMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for VERA with price predictions
Nov 06, 2026

VERA's RSI Indicator climbs out of oversold territory

The RSI Indicator for VERA moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 25 of the 29 cases the stock moved higher. This puts the odds of a move higher at 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on VERA as a result. In 76 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.

The Moving Average Convergence Divergence (MACD) for VERA just turned positive on October 20, 2026. Looking at past instances where VERA's MACD turned positive, the stock continued to rise in 38 of 45 cases over the following month. The odds of a continued upward trend are 84%.

Following a +5.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where VERA advanced for three days, in 238 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

VERA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 53 cases where VERA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.

VERA moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for VERA crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VERA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

The Aroon Indicator for VERA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. VERA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.264) is normal, around the industry mean (3.482). P/E Ratio (-5.074) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VERA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

TECHNICAL ANALYSIS
Technical Analysis
NAMSVERA
RSI
ODDS (%)
Bullish Trend 1 day ago
63%
Bullish Trend 1 day ago
86%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
72%
Bearish Trend 1 day ago
85%
Momentum
ODDS (%)
Bearish Trend 1 day ago
65%
Bullish Trend 1 day ago
79%
MACD
ODDS (%)
Bearish Trend 1 day ago
63%
Bullish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
71%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
72%
Bearish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 6 days ago
78%
Bearish Trend 1 day ago
84%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
83%
Aroon
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
80%
COMPARISON
Comparison
Nov 07, 2026
Stock price -- (NAMS: $18.90 vs. VERA: $29.78)
Brand notoriety: NAMS and VERA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NAMS: 102% vs. VERA: 104%
Market capitalization -- NAMS: $2.26B vs. VERA: $2.15B
NAMS [@Biotechnology] is valued at $2.26B. VERA’s [@Biotechnology] market capitalization is $2.15B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NAMS’s FA Score shows that 2 FA rating(s) are green while VERA’s FA Score has 1 green FA rating(s).

  • NAMS’s FA Score: 2 green, 3 red.
  • VERA’s FA Score: 1 green, 4 red.
According to our system of comparison, NAMS is a better buy in the long-term than VERA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NAMS’s TA Score shows that 4 TA indicator(s) are bullish while VERA’s TA Score has 5 bullish TA indicator(s).

  • NAMS’s TA Score: 4 bullish, 4 bearish.
  • VERA’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both NAMS and VERA are a good buy in the short-term.

Price Growth

NAMS (@Biotechnology) experienced а -5.78% price change this week, while VERA (@Biotechnology) price change was -3.86% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.35%. For the same industry, the average monthly price growth was -10.88%, and the average quarterly price growth was -18.54%.

Reported Earning Dates

NAMS is expected to report earnings on Mar 03, 2027.

VERA is expected to report earnings on Mar 25, 2027.

Industries' Descriptions

@Biotechnology (-2.35% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

VERA and

Correlation & Price change

A.I.dvisor indicates that over the last year, VERA has been loosely correlated with VKTX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if VERA jumps, then VKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VERA
1D Price
Change %
VERA100%
-1.18%
VKTX - VERA
44%
Loosely correlated
+4.07%
SRRK - VERA
42%
Loosely correlated
+3.16%
MGTX - VERA
42%
Loosely correlated
+5.76%
NAMS - VERA
41%
Loosely correlated
+0.05%
TRVI - VERA
41%
Loosely correlated
+11.87%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
TPLS24.520.01
+0.02%
Thornburg Core Plus Bond ETF (TPLS)
WDIV81.84-0.93
-1.13%
State Street SPDR S&P Global Dividend ETF (WDIV)
FXH136.58-1.75
-1.27%
First Trust Health Care AlphaDEX Fund (FXH)
XRPT22.11-2.31
-9.46%
Volatility Shares Trust XRP 2X ETF (XRPT)
MCHU7.32-2.09
-22.21%
Tradr 2X Long MCHP Daily ETF (MCHU)